Form 4: Centessa Pharmaceuticals Acquisition Completed

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company has been finalized, with shareholders receiving cash and contingent value rights.

Summary

• Centessa Pharmaceuticals plc has been acquired by Eli Lilly and Company through a scheme of arrangement.
• The transaction, effective June 24, 2026, involved Eli Lilly's subsidiary, LDH XV Corporation, acquiring all outstanding ordinary shares.
• Shareholders are entitled to receive $38.00 in cash per ordinary share.
• Additionally, shareholders will receive one non-transferable contingent value right (CVR) per ordinary share, with potential contingent payments of up to $9.00 per share based on specified milestones.
• This acquisition was executed under a Transaction Agreement dated March 31, 2026.
• All outstanding and unvested Restricted Share Units (RSUs) were automatically vested and converted into the right to receive the cash consideration and CVR.
• Similarly, all outstanding share options were cancelled and converted into the right to receive cash equal to the excess of the cash consideration over the exercise price, plus one CVR per underlying ordinary share.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for Centessa shareholders, providing a clear cash payout and potential upside through CVRs, indicating a successful exit.

Positives

• Shareholders received a cash payment of $38.00 per ordinary share.
• Shareholders are eligible for potential future payments up to $9.00 per ordinary share through contingent value rights (CVRs).
• The acquisition provides a clear exit for shareholders at a defined price.
• All outstanding equity awards (RSUs and options) were settled, providing value to holders.

Negatives

• The acquisition means Centessa Pharmaceuticals plc will no longer be a publicly traded entity.
• The contingent value of the CVRs is not guaranteed and depends on the achievement of specified milestones.
• The cash consideration of $38.00 per share may not reflect the full potential future value of the company's pipeline, especially if milestones are met.

Risks

• The realization of contingent payments from the CVRs is dependent on Eli Lilly and Company achieving specific, undisclosed milestones.
• There is a risk that the milestones for the CVRs may not be met, resulting in no additional payments to former Centessa shareholders.
• The value of the CVRs is subject to the strategic decisions and execution capabilities of Eli Lilly and Company.

Future Outlook

The future outlook for Centessa Pharmaceuticals plc is now integrated within Eli Lilly and Company. The contingent value rights (CVRs) provide a mechanism for former Centessa shareholders to participate in the future success of specific Centessa assets, with potential payments up to $9.00 per share contingent upon the achievement of specified milestones.

Industry Context

StockSavvy.ai notes that this acquisition by a major pharmaceutical player like Eli Lilly and Company is a common trend in the biotech and pharmaceutical industry, where larger companies acquire smaller, innovative firms to bolster their pipelines. The use of contingent value rights is a standard mechanism to bridge valuation gaps and incentivize the acquirer to achieve development milestones.

Comparison to Industry Standards

• The acquisition price of $38.00 cash plus up to $9.00 in CVRs per share for Centessa Pharmaceuticals plc is a significant premium, reflecting the strategic value of its pipeline assets.
• Many similar acquisitions in the pharmaceutical sector involve cash and CVRs, with the CVR component often ranging from 10-30% of the total deal value, depending on the stage and perceived risk of the underlying assets.
• The structure of the deal, utilizing a scheme of arrangement under UK law, is a common and efficient method for completing public company acquisitions in the United Kingdom.

Stakeholder Impact

• Shareholders: Receive $38.00 cash per share and potential CVR payments, representing a complete exit.
• Employees: Their equity awards (RSUs and options) were converted into cash and CVRs, providing them with financial benefit from the acquisition.
• Creditors: The acquisition by Eli Lilly, a financially strong entity, likely provides security for existing obligations.
• Suppliers: Business relationships may continue under Eli Lilly's management, or be subject to integration and potential changes.

Next Steps

• Former Centessa Pharmaceuticals plc shareholders will receive the $38.00 cash consideration and the contingent value rights.
• Eli Lilly and Company will manage the development and achievement of milestones related to the CVRs.
• The success of the CVRs will depend on Eli Lilly's ability to meet the specified milestones.

Key Dates

Recommendation

For existing Centessa shareholders, the transaction is complete, and they have received their cash and CVRs. For potential investors considering Eli Lilly, this filing is a notification of a completed acquisition and does not directly impact Eli Lilly's stock recommendation beyond its strategic integration.

Keywords

Centessa Pharmaceuticals, Eli Lilly, Acquisition, Scheme of Arrangement, Form 4, Insider Trading, Shareholder Value, Contingent Value Rights, Restricted Share Units, Stock Options, SEC Filing